NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant revenue decline, primarily due to CMS rule changes impacting DPNCheck, and uncertain future revenue from new markets. Despite Quell's growth, overall financial performance is weak, with a net loss and reduced gross margins. The strategic review has not yielded favorable outcomes, and management's unclear responses in the Q&A add to uncertainty. The termination of the ATM equity facility without clear shareholder return strategies further supports a negative outlook. These factors suggest a potential stock price decline in the short term.
Key Financial Performance
Q2 Revenue $769,000 (down 53.6% from $1.656 million in Q2 2023); decline attributed to DPNCheck product line due to CMS rule changes in Medicare Advantage affecting risk adjustment compensation.
Quell Revenue $192,000 (up 47% year-over-year); growth attributed to effective strategic launch and market knowledge.
Gross Profit $492,000 with a gross margin of 64% (down 360 basis points year-over-year); impacted by reduced sales volume affecting indirect cost absorption.
Operating Expenses $2.3 million (down 15% or $422,000 from Q2 2023); decrease due to reduction in force implemented in Q1 2024.
Net Loss $1.488 million or $0.74 per share (improved by $50,000 from a net loss of $1.5 million in Q2 2023).
Operating Cash Usage Approximately $1.4 million (down $90,000 from Q2 2023).
Working Capital $16.9 million at the end of the quarter.
Liquid Assets $16.4 million at the end of the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Quell Revenue Growth: Quell revenue in Q2 of $192,000 was a year-on-year gain of 47%.
CIPN Indication Submission: A de novo submission for CIPN is planned by the fourth quarter of this year.
Quell Starter Kits Sold: 540 Quell starter kits were sold in the quarter, representing 165% year-over-year growth.
Quell Electrode Refills: 3,682 one-month refills of Quell electrodes were sold, showing 13% growth.
Expansion into VA Health System: Quell fibromyalgia is starting to see uptake in the Veterans Administration health system.
International Market Focus: The company is exploring opportunities to monetize non-core assets, particularly in international markets.
Reduction in Force: A reduction in force was implemented, lowering operating expenses by over $0.5 million per quarter.
Cash Usage: Quarterly cash usage is approximately $1.4 million, with plans to decrease further.
Strategic Review Process: The strategic review process is ongoing, with no specific deadline set for completion.
Termination of ATM Equity Facility: The ATM equity facility was terminated following discussions with a large shareholder.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Q2 revenue dropped to $769,000 from $1.656 million in Q2 2023, entirely due to the DPNCheck product line, which was affected by CMS rule changes in Medicare Advantage.
Regulatory Issues: The CMS rule changes initiated a 2-year phaseout of risk adjustment compensation for healthcare providers, impacting peripheral neuropathy screenings and leading to reduced activity from many providers.
Market Uncertainty: The ultimate outcome of efforts to identify new markets for DPNCheck is uncertain, indicating potential risks in revenue generation.
Operational Costs: Despite a reduction in operating expenses, ongoing professional service costs related to strategic reviews may continue to impact financial performance.
Strategic Review Risks: The strategic review process may not result in favorable transactions or outcomes for shareholders, creating uncertainty regarding future business direction.
Market Competition: The company faces competitive pressures in the neurotechnology market, particularly as it seeks to expand its product offerings and market presence.
Economic Factors: The company is navigating economic challenges that may affect consumer spending and healthcare provider budgets, impacting sales and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Review Process: The company is conducting a strategic review process to maximize shareholder value, exploring potential transactions, but has not found any suitable opportunities yet.
Reduction in Force: A substantial reduction in force was implemented to lower operating expenses by over $0.5 million per quarter.
Monetization of Non-Core Assets: The company is exploring opportunities to monetize non-core assets, particularly in international markets.
Quell Product Growth: Quell revenue grew by 47% year-over-year, with plans to restart the OTC business by Q4 2024.
CIPN Indication Submission: A de novo submission for chemotherapy-induced peripheral neuropathy (CIPN) is planned for Q4 2024, with a potential commercial launch by the end of 2025.
Revenue Expectations: Q2 2024 revenue was $769,000, a decline from $1.656 million in Q2 2023, primarily due to DPNCheck.
Future Revenue from New Markets: The company is working on new market opportunities for DPNCheck, but meaningful revenue is expected to take several quarters.
Operating Expenses: Operating expenses in Q2 2024 were $2.3 million, down 15% from the prior year, with further reductions expected.
Gross Margin: Gross margin for Q2 2024 was 64%, with individual product margins stable for DPNCheck and improving for Quell.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: The company is actively exploring opportunities to maximize shareholder value, including a strategic review process that has been ongoing for six months. However, the Board has determined that none of the potential transactions considered are in the best interest of shareholders at this time.
ATM Equity Facility: The company terminated its at-the-market ATM equity facility as part of its strategic review process.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are you really going to grow the Quell business since the DPN business is really dropping off?
A:We've been in the prescription market for about six quarters. We have not invested heavily on the commercial side. We want to understand the business and how to grow it efficiently before we invest significant cash. We believe the growth opportunity is there, and we're ready to start increasing those investments.
Q:How do you address the product's effectiveness and side effects?
A:Quell fibromyalgia provides symptom relief, particularly for pain, with minimal side effects. Feedback from the market has been excellent, and we are optimistic about its effectiveness and safety profile.
Q:Are you going to approach the OTC market differently this time?
A:The OTC business will be primarily online through our e-commerce site. We will consider Amazon but are cautious about margins and the attractiveness of brick-and-mortar retail.
Q:Review of Unclear Management Responses
A:Management did not provide specific details on the timeline for growth or the exact strategies for penetrating the VA market, which could be seen as avoiding a direct answer.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advantage phaseout
Instructions
JM Cohen
OTC
Quell fibromyalgia
Senior Vice
Shai Founder
VA
activity
addition
adjustment compensation
answer opportunity
asset cash
basis margin
change Medicare
commerce
contract rep
cost
counter
director
drop
end
fibromyalgia indication
focus
indication CIPN
interest
market product
outcome
phaseout risk
prescription market
provider
reduction force
review process
screening neuropathy
sign
software
transaction
usage capital
NURO Transcript
NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call reveals significant revenue decline, primarily due to CMS rule changes impacting DPNCheck, and uncertain future revenue from new markets. Despite Quell's growth, overall financial performance is weak, with a net loss and reduced gross margins. The strategic review has not yielded favorable outcomes, and management's unclear responses in the Q&A add to uncertainty. The termination of the ATM equity facility without clear shareholder return strategies further supports a negative outlook. These factors suggest a potential stock price decline in the short term.
NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript
Unknown2-22
The earnings call summary reveals several concerning factors: declining gross margins, increased operating expenses, expanding net loss, strategic uncertainty for key products, and reliance on a single product in early commercialization. Additionally, revenue and gross profit have significantly decreased, and the use of an ATM facility for stock sales raises governance concerns. The Q&A section highlights strategic uncertainties and management's evasive responses. Given these issues, the stock is likely to experience a strong negative reaction.
NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript
Neutral10-27
NeuroMetrix Inc. (NURO) Q2 2023 Earnings Call Transcript
Neutral7-27
NURO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
